BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 7544131)

  • 21. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
    Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
    APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract.
    Berstad AE; Brandtzaeg P
    Gut; 1998 Apr; 42(4):522-9. PubMed ID: 9616315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human nasal epithelium adsorbs complement C3-related fragments and expresses cell membrane complement regulatory proteins.
    Varsano S; Frolkis I; Shapiro H; Ophir D
    Laryngoscope; 1996 May; 106(5 Pt 1):599-604. PubMed ID: 8628088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
    Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
    Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of complement regulating factors in gastric cancer cells.
    Inoue T; Yamakawa M; Takahashi T
    Mol Pathol; 2002 Jun; 55(3):193-9. PubMed ID: 12032231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of the complement regulatory proteins in the normal human kidney.
    Ichida S; Yuzawa Y; Okada H; Yoshioka K; Matsuo S
    Kidney Int; 1994 Jul; 46(1):89-96. PubMed ID: 7523758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.
    Terstappen LW; Nguyen M; Lazarus HM; Medof ME
    J Leukoc Biol; 1992 Dec; 52(6):652-60. PubMed ID: 1281489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.
    Miyagawa S; Mikata S; Shirakura R; Matsuda H; Nagasawa S; Terados A; Hatanaka M; Matsumoto M; Seya T
    Scand J Immunol; 1996 Apr; 43(4):361-6. PubMed ID: 8668913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement-regulatory proteins in ovarian malignancies.
    Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
    Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage.
    Venneker GT; van den Hoogen FH; Boerbooms AM; Bos JD; Asghar SS
    Lab Invest; 1994 Jun; 70(6):830-5. PubMed ID: 7516986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue.
    Murray KP; Mathure S; Kaul R; Khan S; Carson LF; Twiggs LB; Martens MG; Kaul A
    Gynecol Oncol; 2000 Feb; 76(2):176-82. PubMed ID: 10637067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.
    Sakuma T; Kodama K; Hara T; Eshita Y; Shibata N; Matsumoto M; Seya T; Mori Y
    Jpn J Cancer Res; 1993 Jul; 84(7):753-9. PubMed ID: 7690355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells.
    van den Berg CW; Rix C; Hanna SM; Perez de la Lastra JM; Morgan BP
    Transplantation; 2000 Aug; 70(4):667-73. PubMed ID: 10972227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques.
    Yasojima K; Schwab C; McGeer EG; McGeer PL
    Arterioscler Thromb Vasc Biol; 2001 Jul; 21(7):1214-9. PubMed ID: 11451754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.